|
Infectious Agents and Cancer Volume 3
|
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
Research articleHuman herpesvirus-8 (HHV-8) sero-detection and HIV association in Kaposi's sarcoma (KS), non-KS tumors and non-neoplastic conditionsAmos R Mwakigonja1,2 , Pawan Pyakurel1 , Parviz Kokhaei3,4 , Fatemeh Pak1,3 , Leonard K Lema5 , Ephata E Kaaya1,2 and Peter Biberfeld1  1Immunopathology Laboratory, Department of Oncology-Pathology, Cancercentrum Karolinska (CCK), Karolinska University Hospital Solna/Karolinska Institutet, Stockholm, Sweden 2Department of Pathology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania 3Department of Immunology, Semnan Medical University, Semnan, Iran 4Immune and Gene Therapy Lab., Cancercentrum Karolinska (CCK) Karolinska University Hospital Solna/Karolinska Institutet, Stockholm, Sweden 5Department of Surgery, MUHAS and Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania author email corresponding author email
Infectious Agents and Cancer 2008,
3:10doi:10.1186/1750-9378-3-10 Abstract
Background
The association of the human herpesvirus-8/Kaposi's sarcoma (KS)-associated herpesvirus (HHV-8/KSHV) serology with various malignancies in Tanzania is not currently well established while previous studies were based on either PCR or immunofluorescence assays [IFA] but not with a sensitive enzyme-linked immunosorbent assay (ELISA). Selected archival diagnostic biopsies (n = 184) and sera from indigenous patients with KS (n = 120), non-KS tumors (n = 24) and non-neoplastic lesions (n = 40) at Muhimbili National Hospital (MNH), Tanzania, were evaluated by diagnostic histopathology, immunohistology [anti-HHV-8 latency-associated nuclear antigen (LANA)] and serology for HIV (ELISA) and HHV-8 (IFA and ELISA).
Results
About 66.3% (n = 122) cases including AIDS-associated Kaposi's sarcoma (AKS) (n = 93), reactive conditions (n = 28) and only one non-KS tumour were HIV positive. Endemic KS (EKS) patients were mostly males (96.3%, 26/27) who were less (69.9%, 65/93) predominant in AIDS-associated (AKS). A high (89%) percentage of patients with anti-HHV-8 antibodies was found in the cohort including the HIV positive (92%) cases, males (81.2%), KS patients (93%), non-KS tumors (92%), and reactive conditions (75%). All HHV-8 seronegative KS cases were nodular stage whereas both sera and corresponding biopsies from early stage KS were HHV-8+. Assay sensitivity, positive predictive value (PPV) and specificity were 98.6%, 93.5% and 16.7% for IFA and 93.5%, 98.6% and 50.0% for ELISA respectively.
Conclusion
HHV-8 seroprevalence at MNH appears high as expected among AKS cases and males but also in non-KS patients. ELISA showed a combination of high HHV-8 sensitivity as well as higher PPV and specificity than IFA which however, showed higher sensitivity. The apparent stage-dependent, inverted serum HHV-8 immunoreactivity supports a notion of viral immune-segregation during KS development. Routine HHV-8 screening should be considered particularly in patients at risk of KS and for selection of blood/organ donations. |